top of page

Tue, 27 Oct


Zoom only!

An Investor event on Synthetic Biology

In the first half of 2020, Synthetic Biology companies, boosted by the impact of the Corona virus, raised over $3 billion in investments. Find out more about this booming new technology in our live and zoom event!

Registration is Closed
See other events
An Investor event  on Synthetic Biology

Time & Location

27 Oct 2020, 08:15 – 10:15 EET

Zoom only!

About the Event

An Investor event  on Synthetic Biology

Join with Zoom:

We have compiled an information package for investors on our site > here.

This event requires you to wear a mask. We will provide masks to those who need them.

Sixty-five synthetic biology companies raised $1.9 billion, in the first half of 2019. In the first half of 2020, despite the cooling effect of Corona virus on the global economy, fifty-six synbio companies raised over $3 billion. It is clear, the bioeconomy, by some estimates worth $4 trillion, is booming. Learn more about this exciting new technology in our Breakfast event!

What is Synthetic Biology?

Synthetic biology, the ability to program living organisms, is expected to enable the next industrial revolution. The rapid development of the field is powered by  AI and automation and robotics drastically dropping the price of technology. Synthetic biology offers a solution to turn waste streams and carbon emissions into useful raw materials and the acute need to find treatments for novel diseases like corona.. This coming manufacturing revolution means programming single cells to produce pharmaceuticals, materials, chemicals, food and fuels. As an investment opportunity synbio resembles the tech industry of the 80's and the 90's.

The current situation with coronavirus will give synthetic biology an unprecedented boost. A sense of urgency that the discipline has been waiting for has come from an unwanted direction. Synthetic biology, combined with the capabilities of the increasing computational power, offers potential solutions to fighting and preventing viruses. This will bring the science and its applications into mainstream and open up its possibilities for broader use.


8:15 Welcome!

8:20 What is Synthetic Biology?

8:25  Innovation through collaboration

Perttu Koskinen VP of Innovation, Discovery and External Collaboration at Neste

8:50  The Opportunity of Life

How does Synthetic Biology look like as an investment opportunity? The trends, some case studies and a global investment overview.

Tuula Palmén and Nina Pulkkis from Synbio Powerhouse

9:10  Greetings From the Emerging World of Impact Investing

Jussi Nykänen / Managing Director at FIM Impact Investing

9:20 Synbio Powerhouse Business Finland Growth engine start

Kenneth Salonius, Head of Business Development at Vertical

9:35  Networking & Q&A in Zoom

Tuula Palmén (PhD, EMBA) is the co-creation manager of Synbio Powerhouse, the leading synthetic biology hub in Finland, powered by VTT. Before joining VTT Tuula was the Head of Health Capital Helsinki Alliance and earlier Director, Life Science in Business Oulu.

Nina Pulkkis is a science journalist and the director of the science documentary series The Future of Finland. She runs the communications for Synbio Powerhouse and is the creator of Korvaa-project, in which a pair of headphones were assembled with bioengineered materials. Last year the project news coverage reached over 400 million readers around the world.

Jussi Nykänen (M.Sc. Lic. Dsc Tech. ) is the Managing Director at FIM Impact Investing. He has extensive experience in managing and supervising operations in various fields of environmental business. These cover i.a. environmental and cleantech policies, fund management, project financing and project implementation as well as activities for internationalization and expansion of early-stage cleantech businesses

Perttu Koskinen (DSc Tech) VP of Innovation, Discovery and External Collaboration at Neste

Perttu leads Discovery and External Collaboration Unit at Neste Innovation Function. His unit is responsible for identification and development of new technology and business opportunities as well as establishing external R&D&I partnerships and consortia for innovation at Neste. He holds Doctor in Technology degree in environmental biotechnology  from Tampere University of Technology, Finland, and has 12 years of industrial R&D experience in development of technologies for renewable fuels and chemicals. He is the author in 14 scientific peer-review articles and inventor in more than 20 patent applications.

Kenneth Salonius, Co-founder and Head of Business Development at Vertical. With an enviable track record in successful startup founding and design (HealthSpa & Framgo), his main focus is on systematically bringing innovative startups and ambitious corporates together to create and develop profitable enterprises.

Zoom meeting details:

Topic: Synthetic Biology for Investors

Time: Oct 27, 2020 08:15 AM Helsinki

Join Zoom Meeting

Meeting ID: 943 1970 2380

One tap mobile

+13126266799,,94319702380# US (Chicago)

+13462487799,,94319702380# US (Houston)

Dial by your location

+1 312 626 6799 US (Chicago)

+1 346 248 7799 US (Houston)

+1 669 900 6833 US (San Jose)

+1 929 205 6099 US (New York)

+1 253 215 8782 US (Tacoma)

+1 301 715 8592 US (Germantown)

Meeting ID: 943 1970 2380

Find your local number:

Share This Event

bottom of page